Skip to Content

Posts tagged with "Cancer"

  • Biological News

    The Motions of a Protein

    So, people like me spend their time trying to make small molecules that will bind to some target protein. So what happens, anyway, when a small molecule binds to a target protein? Right, right, it interacts with some site on the thing, hydrogen bonds, hydrophobic interactions, all that – but what really happens? That’s surprisingly… Read More
  • Cancer

    Kinases: Hot or Not?

    For the last ten or fifteen years, untold amounts of time and money have been spent developing drugs to inhibit kinase enzymes. Just go take a look at KinasePro’s archives; that’ll give you the idea. Huge programs have been run at all the major drug companies, and any number of smaller ones have been founded… Read More
  • Cancer

    Curse Of the Lost Compounds

    There are some groups of compounds that seem to have a curse on them. They show up in drug screening, they have activity that’s often too good to ignore, but hardly anyone can manage to turn one of them into a drug. Trifluoromethyl ketones are one example of this. They’re classic inhibitors of proteases, especially… Read More
  • Cancer

    Sunesis: No Substitutions Allowed?

    A colleague mentioned to me the other day that Sunesis Pharmaceuticals had let many of its remaining research staff go back during the summer – they’re battening down to try to get their main clinical candidate through for leukemia and ovarian cancer. That’s a common phase of life for a small company trying to go… Read More
  • Business and Markets

    BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra

    I haven’t mentioned the attempt by Bristol-Meyers Squibb to buy out Imclone until now, but there’s a nice . The reasons for the move are unsurprising – BMS would like all the revenue from Erbitux, instead of just a share of it, and sees some value coming up in Imclone’s pipeline (such as their development… Read More
  • Cancer

    The Complicated Causes of Cancer

    Since I was just banging on the table (or the lab bench) the other day about how many diseases aren’t single-factor, and about how many diseases (like cancer) aren’t even single diseases, I thought this would be a good time to haul out some evidence for that. The data are here thanks to some recent… Read More
  • Business and Markets

    GSK Layoffs: Yes, Again

    The ax is falling again at GlaxoSmithKline. This time it’s the oncology group. Last month the cardiovascular people got this same treatment, you’ll recall, and there was some disagreement about how many jobs were being affected. But it looks like the company is moving one by one through its Centers of Excellence in Drug Discovery… Read More
  • Business and Markets

    Vytorin: Another Round of Nasty Results

    Merck took the unusual step of delaying its earnings release yesterday until after the close of the market. A report on another clinical study of Vytorin (ezetimibe), their drug with Schering-Plough, was coming out, so they put the numbers on hold until after the press release yesterday afternoon. Naturally, this led to a lot of… Read More
  • Cancer

    Auroral Activity

    If you go to the med-chem or pharmacology literature databases and type “Aurora kinase”, you’d better stand back. A geyser of publications will come spraying out, most of them having to do with Aurora A and/or Aurora B as possible targets for cancer therapy. These enzymes are involved in different phases of cell division, among… Read More
  • Cancer

    And You Thought Exubera Was A Disaster Before

    I don’t usually do more than one post a day, but this really caught my eye. In an ongoing review of Pfizer’s (now discontinued) inhaled insulin (Exubera), an increased chance of lung cancer has turned up among participants in the clinical trials. Six of the over four thousand patients in the trials on Exubera have… Read More